These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 8756654

  • 1. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function.
    Ludwig RL, Bates S, Vousden KH.
    Mol Cell Biol; 1996 Sep; 16(9):4952-60. PubMed ID: 8756654
    [Abstract] [Full Text] [Related]

  • 2. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest.
    Ryan KM, Vousden KH.
    Mol Cell Biol; 1998 Jul; 18(7):3692-8. PubMed ID: 9632751
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function.
    Kong XT, Gao H, Stanbridge EJ.
    J Biol Chem; 2001 Aug 31; 276(35):32990-3000. PubMed ID: 11395510
    [Abstract] [Full Text] [Related]

  • 4. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
    Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B, Crook T, Inga A, Resnick MA, Iggo R, Fronza G.
    Oncogene; 2001 Jun 14; 20(27):3573-9. PubMed ID: 11429705
    [Abstract] [Full Text] [Related]

  • 5. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
    Kokontis JM, Wagner AJ, O'Leary M, Liao S, Hay N.
    Oncogene; 2001 Feb 08; 20(6):659-68. PubMed ID: 11313999
    [Abstract] [Full Text] [Related]

  • 6. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.
    Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, Vousden KH.
    EMBO J; 1996 Feb 15; 15(4):827-38. PubMed ID: 8631304
    [Abstract] [Full Text] [Related]

  • 7. The Brn-3a transcription factor inhibits the pro-apoptotic effect of p53 and enhances cell cycle arrest by differentially regulating the activity of the p53 target genes encoding Bax and p21(CIP1/Waf1).
    Budram-Mahadeo V, Morris PJ, Latchman DS.
    Oncogene; 2002 Sep 05; 21(39):6123-31. PubMed ID: 12203124
    [Abstract] [Full Text] [Related]

  • 8. Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment. WAFI/Cip1 = WAF1/Cip1.
    Zacharatos PV, Gorgoulis VG, Kotsinas A, Manolis EN, Liloglou T, Rassidakis AN, Kanavaros P, Field JD, Halazonetis T, Kittas C.
    Anticancer Res; 1999 Sep 05; 19(1A):579-87. PubMed ID: 10226602
    [Abstract] [Full Text] [Related]

  • 9. TNF-alpha induced p21(WAF1) but not Bax in colon cancer cells WiDr with mutated p53: important role of protein stabilization.
    Kobayashi N, Takada Y, Hachiya M, Ando K, Nakajima N, Akashi M.
    Cytokine; 2000 Dec 05; 12(12):1745-54. PubMed ID: 11097743
    [Abstract] [Full Text] [Related]

  • 10. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A, Resnick MA.
    Oncogene; 2001 Jun 07; 20(26):3409-19. PubMed ID: 11423991
    [Abstract] [Full Text] [Related]

  • 11. Ets1 is required for p53 transcriptional activity in UV-induced apoptosis in embryonic stem cells.
    Xu D, Wilson TJ, Chan D, De Luca E, Zhou J, Hertzog PJ, Kola I.
    EMBO J; 2002 Aug 01; 21(15):4081-93. PubMed ID: 12145208
    [Abstract] [Full Text] [Related]

  • 12. Relationship of sequence-specific transactivation and p53-regulated apoptosis in interleukin 3-dependent hematopoietic cells.
    Gottlieb E, Lindner S, Oren M.
    Cell Growth Differ; 1996 Mar 01; 7(3):301-10. PubMed ID: 8838860
    [Abstract] [Full Text] [Related]

  • 13. Transcriptional regulation during p21WAF1/CIP1-induced apoptosis in human ovarian cancer cells.
    Wu Q, Kirschmeier P, Hockenberry T, Yang TY, Brassard DL, Wang L, McClanahan T, Black S, Rizzi G, Musco ML, Mirza A, Liu S.
    J Biol Chem; 2002 Sep 27; 277(39):36329-37. PubMed ID: 12138103
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions.
    Blagosklonny MV, Giannakakou P, Romanova LY, Ryan KM, Vousden KH, Fojo T.
    Carcinogenesis; 2001 Jun 27; 22(6):861-7. PubMed ID: 11375890
    [Abstract] [Full Text] [Related]

  • 15. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
    Fulci G, Ishii N, Maurici D, Gernert KM, Hainaut P, Kaur B, Van Meir EG.
    Cancer Res; 2002 May 15; 62(10):2897-905. PubMed ID: 12019170
    [Abstract] [Full Text] [Related]

  • 16. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines.
    Aurelio ON, Kong XT, Gupta S, Stanbridge EJ.
    Mol Cell Biol; 2000 Feb 15; 20(3):770-8. PubMed ID: 10629033
    [Abstract] [Full Text] [Related]

  • 17. A novel p53 mutant retained functional activity in lung carcinomas.
    Ko JL, Chiao MC, Chang SL, Lin P, Lin JC, Sheu GT, Lee H.
    DNA Repair (Amst); 2002 Sep 04; 1(9):755-62. PubMed ID: 12509279
    [Abstract] [Full Text] [Related]

  • 18. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression.
    Venot C, Maratrat M, Dureuil C, Conseiller E, Bracco L, Debussche L.
    EMBO J; 1998 Aug 17; 17(16):4668-79. PubMed ID: 9707426
    [Abstract] [Full Text] [Related]

  • 19. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F.
    Cancer Res; 1996 Feb 01; 56(3):556-62. PubMed ID: 8564971
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
    Shinagawa Y, Kawamata H, Omotehara F, Nakashiro K, Hoque MO, Furihata T, Horiuchi H, Imai Y, Fujimori T, Fujibayashi T.
    Int J Oncol; 2003 Feb 01; 22(2):383-9. PubMed ID: 12527938
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.